First Tracks Biotherapeutics, Inc. (TRAX) stock
TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
First Tracks Biotherapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for First Tracks Biotherapeutics
First Tracks Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?